Join the 'Candida Infections' group to help and get support from people like you.
Candida Infections News
Posted 13 Jan 2017 by Drugs.com
-- Skin infections are common in athletes, often triggered by sweaty equipment that rubs against skin. The American Academy of Orthopaedic Surgeons offers these prevention tips: Wash your hands often with soap and water. Or use a hand sanitizer. Take a shower as soon as possible after practice or a game. After each use, wash and thoroughly dry your uniform. Never share personal items, such as ...
Posted 4 Nov 2016 by Drugs.com
FRIDAY, Nov. 4, 2016 – Federal health officials say 13 cases of a potentially deadly, drug-resistant fungal infection have been reported in the United States. Four of those cases ended in death, but health officials said it's not clear if the deaths were due to the infection or the patients' underlying health conditions. Candida auris fungal infection is emerging as a health threat worldwide, ...
Posted 10 Feb 2016 by Drugs.com
WEDNESDAY, Feb. 10, 2016 – Wrestlers are much more likely to suffer skin infections than other U.S. high school athletes, new research shows. The study authors examined five years of data on skin infections among athletes in 22 high school sports. Nearly 74 percent of skin infections occurred among wrestlers, and just under 18 percent among football players, the investigators found. The actual ...
FDA Medwatch Alert: Noxafil (posaconazole): Drug Safety Communication - Dosing Errors when Switching between Different Oral Formulations; Label Changes Approved
Posted 4 Jan 2016 by Drugs.com
ISSUE: The FDA is cautioning that differences in dosing regimens between the two oral formulations of the antifungal Noxafil (posaconazole) have resulted in dosing errors. To help prevent additional medication errors, the drug labels were revised to indicate that the two oral formulations cannot be directly substituted for each other but require a change in dose. Direct mg for mg substitution o ...
Posted 26 Nov 2013 by Drugs.com
WHITEHOUSE STATION, N.J., Nov. 26, 2013--(BUSINESS WIRE)--Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved Noxafil (posaconazole) 100 mg delayed-release tablets. Noxafil delayed-release tablets are a new formulation with a loading dose of 300 mg (three 100 mg delayed-release tablets) twice daily on the first ...
Ask a Question
Related Condition Support Groups
Related Drug Support Groups
fluconazole, Diflucan, itraconazole, Sporanox, voriconazole, amphotericin b, AmBisome, amphotericin b liposomal, amphotericin b lipid complex, view more... micafungin, Eraxis, Vfend, Fungizone, Cancidas, Mycamine, Noxafil, Sporanox PulsePak, Abelcet, flucytosine, Ancobon, caspofungin, Amphocin, amphotericin b cholesteryl sulfate, Amphotec, anidulafungin, posaconazole, Onmel